The Role of Glasses in Aseptic Production: A Detail Often Ignored - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of Glasses in Aseptic Production: A Detail Often Ignored


Pharmaceutical Technology



Figure 2: Sterilization graphic to wave quadrant that enables us to verify the D value to one sterilization´s specific temperature.
An autoclave known as a BIER-vessel must be used to evaluate the D value. The most important characteristic of this autoclave is its ability to produce a sterilization graphic to wave quadrant (see Figure 2), which allowed the verification of the D value to one sterilization cycle's specific temperature.

Results

Facial adherence and transmittance checks. The facial adherence did not change after 30 steam sterilization cycles. The goggles maintained their adherence without any shape modification caused by steam.

Even if the transmittance variations are minimal and can be attributed to measurement uncertainty, we verified that the transmission increased slightly with the increase in the number of sterilization cycles. The 84.1% transmittance value of the lenses increased to about 2 points after 20 cycles. After 30 cycles, transmittance decreased slightly under the starting value because of the appearance of superficial sediment and slight blurring of the lenses' surface. In any case, we concluded that after 30 sterilization cycles, the transmittance does not vary significantly. In fact, for all tested samples, transmittance was more than 75%, which linked with a check of the unchanging lenses' surface transparency, guaranteed that high visibility was maintained.

Particle-release check. Particle-release results for glasses subjected to repeated sterilization cycles were analyzed separately for the visor (lenses and support) and the elastic strip.


Figure 3: Percentage of particles in the 0.2–1.0 mm range released by the frames during the autoclave cycles.
Check of the visor particle release. The particles' cumulative calculation, in the range between 0.2 and 1.0 μm, shows a proportional linear growth of the total particles compared with the autoclave cycles to which the glasses were submitted (see Figure 3).

The contribution is given by the particles with diameters smaller than 0.2 µm that reach values greater than 90% of the total after 10 sterilization cycles, with exponential growth. The 0.4, 0.6, 0.8, and 1.0-μm diameter particles decrease with analogous progression.

The glasses' particle release, in the considered dimensional range, may be attributed to pollution of the sample obtained after repeated autoclave cycles. The polymer reticule of the glasses could favor the inclusion of the 0.2-μm dimension particles that are in the water used for the autoclave feeding and used as washing water before the analysis. The high temperatures to which the glasses were subjected favor plastic material expansion and the introduction of particles with smaller dimensions.

The 0.4–1.0-μm particles that quickly decrease to values lower than 10% of the total after 10 sterilization cycles were present on the sample's surface and not inside the polymer, because they would not be able to imbed themselves during the autoclave cycles and were washed away from the glasses' surface.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here